New study monitors Real-World use of LIVTENCITY for Post-Transplant CMV
NCT ID NCT06555432
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study follows 168 adults in South Korea who have had a transplant and developed a CMV infection that didn't respond to other treatments. They will take LIVTENCITY (Maribavir) as part of routine care, and researchers will track side effects and how well the drug clears the virus over about 5 months. The goal is to see if the medicine works safely in everyday practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS (CMV) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Catholic University of Korea, Seoul ST. Mary's Hospital
RECRUITINGSeoul, 06591, South Korea
Contact
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Maribavir (LIVTENCITY tablet)
What this could lead to
If successful, this study will confirm that Maribavir is safe and effective for treating CMV after transplant in real-world settings, helping doctors manage this serious infection.
What could go wrong
This is an observational post-marketing study, not a controlled trial, so results may be less definitive. Side effects or lack of effectiveness could still occur in some patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.